Spinal muscular atrophy outcome measures

Revision as of 14:40, 28 January 2012 by Priyamvada Singh (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search

Spinal Muscular Atrophy Microchapters

Home

Patient Info

Overview

Epidemiology and Demographics

Risk Factors

Screening

Other forms

Molecular Biology

Genetics

Types

Diagnosis

Diagnosis

Full Differential Diagnosis

Symptom

Physical Examination

Electrolyte & Biomarker Studies

Electrocardiogram

Chest X Ray

MRI and CT

Echocardiography or Ultrasound

Other Imaging Findings

Pathology

Other Diagnostic Studies

Treatment

Outcome measures

Therapeutics development

Indications For Surgery

Research

Pre-Operative Assessment

Post-Operative Assessment

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Spinal muscular atrophy outcome measures Resources

Most recent articles on Spinal muscular atrophy outcome measures

Most cited articles on Spinal muscular atrophy outcome measures

Review articles on Spinal muscular atrophy outcome measures

Review articles on Spinal muscular atrophy outcome measures

CME Programs on Spinal muscular atrophy outcome measures

Powerpoint slides on Spinal muscular atrophy outcome measures

Images of Spinal muscular atrophy outcome measures

Ongoing Trials on Spinal muscular atrophy outcome measures at Clinical Trials.gov

US National Guidelines Clearinghouse on Spinal muscular atrophy outcome measures

NICE Guidance on Spinal muscular atrophy outcome measures

FDA on Spinal muscular atrophy outcome measures

CDC on Spinal muscular atrophy outcome measures

Spinal muscular atrophy outcome measures in the news

Blogs on Spinal muscular atrophy outcome measures

Directions to Hospitals Treating Spinal muscular atrophy outcome measures

Risk calculators and risk factors for Spinal muscular atrophy outcome measures

Editors-in-Chief: C. Michael Gibson, M.S., M.D.; Priyamvada Singh, MBBS

Overview

There is currently no cure for spinal muscular atrophy. There has been great interest in identifying agents that can increase the amount of full- length SMN protein by upregulating expression of the SMN2 gene. Many clinical trials are ongoing to find the most reliable outcome measures.

Several new outcome measures have shown encouraging results and helped in designing future clinical trials. Some of them currently used in clinical trials are as follows –

  • Quantitative muscle ultrasound
  • The Six-Minute Walk Test (6MWT) – In case of ambulatory SMA patients.
  • 10 minute walk/run test
  • The Hammersmith Motor Scale
  • The Hammersmith Functional Motor Scale Expanded (HFMSE)
  • Knee flexor strength test
  • The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)
  • The Gross Motor Function Measurement
  • Motor unit number estimation (MUNE)
  • Compound motor action potential (CMAP) amplitude
  • Serologic biomarkers (SMN mRNA and protein levels)

References

da:Spinal muskulær atrofi de:Spinale Muskelatrophie el:Νωτιαία μυϊκή ατροφία nl:Spinale Musculaire Atrofieën fi:Spinaaliset lihasatrofiat sv:Spinal muskelatrofi



Linked-in.jpg